Thyrocare To Sell Nuclear Healthcare Stake For ₹141.4 Crore To Trovera

Market snapshot: Thyrocare Technologies Ltd's Board has approved the sale of its 100% stake in Nuclear Healthcare Limited to Trovera Healthcare Private Limited for ₹141.4 crore. This transaction represents a complete exit from the capital-intensive radiology business, allowing the company to concentrate capital on its high-growth pathology segment. Concurrently, Thyrocare will purchase operating diagnostic laboratory premises in Gurugram and Hyderabad from Nuclear Healthcare for ₹20.59 crore to secure post-divestment operations.

Data Snapshot

• The aggregate divestment value for the entire shareholding of Nuclear Healthcare Limited comprising 1,11,11,000 equity shares is approximately ₹141.4 crore.
• The consideration is structured as a cash payment of approximately ₹81.9 crore and a non-cash allotment of Trovera's Compulsorily Convertible Preference Shares valued at ₹59.5 crore.
• As part of the consideration, Thyrocare will acquire 42,500 CCPS of Trovera Healthcare Private Limited at an issue price of ₹14,000 per share.
• Thyrocare will purchase operating land and buildings located in Gurugram, Haryana, and Hyderabad, Telangana, from Nuclear Healthcare for ₹20.59 crore.

What's Changed

• Previously, Thyrocare operated its diagnostic laboratories in Gurugram and Hyderabad from leased premises owned by Nuclear Healthcare. It will now gain outright ownership of these assets, eliminating lease rent overheads post-divestment.
• The diagnostic chain shifts from a dual-business pathology and radiology model to an absolute focus on the pathology diagnostics market.

Key Takeaways

• Board approves complete exit from radiology business via sale of 100% of Nuclear Healthcare Limited to Trovera.
• Total transaction value for the divestment stands at approximately ₹141.4 crore, featuring ₹81.9 crore cash and ₹59.5 crore Trovera convertible preference shares.
• Concurrently, Thyrocare acquires operating laboratory land and buildings in Gurugram and Hyderabad for ₹20.59 crore.
• The realignment is aimed at channeling capital and resources into the highly scalable core pathology segment.

SAHI Perspective

Exiting the capital-intensive radiology business is a positive operational pivot for Thyrocare. Radiology requires continuous capital expenditure to maintain and upgrade equipment. The transaction structures a neat reinvestment, as the company uses a portion of the cash proceeds to secure its laboratory real estate assets in Gurugram and Hyderabad, ensuring its core pathology infrastructure remains unaffected by the divestment.

Market Implications

The exit from the asset-heavy radiology segment will likely improve Thyrocare's return on capital employed (ROCE) and operating margins over the medium term. The ₹81.9 crore cash inflow strengthens the balance sheet, though the holding of ₹59.5 crore of Trovera preference shares exposes it to potential illiquidity or private market valuation adjustments.

Trading Signals

Market Bias: Bullish

Exiting the asset-heavy radiology business for ₹141.4 crore improves operating efficiency and ROCE. Concurrently, acquiring key laboratory properties in Gurugram and Hyderabad for ₹20.59 crore secures critical revenue-generating pathology infrastructure.

Overweight: Healthcare Services, Diagnostic Laboratories

Trigger Factors:

• Shareholder approval for the divestment and property purchase.
• Successful execution of the Share Purchase Agreement (SPA).
• Utilization of the ₹81.9 crore cash component for pathology expansion.

Time Horizon: Medium-term (3-12 months)

Industry Context

The Indian diagnostics industry is transitioning from aggressive price competition to premium wellness packages and specialty pathology tests. Pathology diagnostics present significantly higher scalable business profiles and better capital returns compared to heavy equipment-based radiology services.

Key Risks to Watch

• Risk of shareholder non-approval for the proposed transactions.
• Risk of illiquidity or valuation volatility with Trovera's Compulsorily Convertible Preference Shares (CCPS).
• Transition and execution delays in handing over Nuclear Healthcare's operational systems.

Recent Developments

In August 2026, promoter Docon Technologies Private Limited sold a 9.90% stake in Thyrocare through market trades for ₹986 crore, reducing its holding to 51.02% to help parent API Holdings repay its debt. For Q1 FY27, Thyrocare reported a strong financial performance with consolidated revenue rising 24.3% YoY to ₹240.02 crore, and net profit climbing 34.1% YoY to ₹51.33 crore.

Closing Insight

Tactically divesting non-core segments to fund the acquisition of core diagnostic real estate assets represents an effective corporate clean-up. This asset realignment positions Thyrocare as an agile, pathology-focused player with improved capital efficiency.

High Performance Trading with SAHI.